ArticleCancer science2026
Real-World Achievement of Guideline-Concordant Treatment and Survival in Osteosarcoma: A Nationwide Registry Study.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Real-world achievement of guideline-concordant treatment in osteosarcoma remains unclear. This study aimed to determine stage-specific rates of guideline-concordant treatment, evaluate their association with survival outcomes, and identify factors associated with non-concordance. Patients with osteosarcoma between 2011 and 2020 were identified from the Japanese Bone and Soft Tissue Tumor Registry. Rates of guideline-concordant treatment and disease-specific survival (DSS) were investigated. Among 1149 patients, 969 (84%) received guideline-concordant treatment. Achievement rates were 85% for localized low-grade, 83% for localized high-grade, and 90% for metastatic osteosarcoma. In localized low-grade disease, guideline-concordant treatment was associated with superior 5-year DSS (97% vs. 68%, p = 0.007); trunk location was associated with non-concordance. In localized high-grade disease, guideline-concordant treatment was also associated with superior 5-year DSS (78% vs. 50%, p < 0.001); age > 40 years and trunk location were associated with non-concordance. The association between guideline-concordant treatment and superior DSS was observed in both patients ≤ 40 years (82% vs. 50%; p < 0.001) and > 40 years (61% vs. 50%; p = 0.030). However, in a sensitivity analysis restricted to localized high-grade extremity osteosarcoma, this association remained significant among patients aged ≤ 40 years. In metastatic disease, guideline-concordant treatment was associated with superior 2-year DSS (54% vs. 16%; p < 0.001). Overall, guideline-concordant treatment was associated with superior survival outcomes in osteosarcoma. Treatment feasibility appeared to substantially influence treatment achievement and survival, particularly among older patients. No significant geographic disparities in achievement rates were observed across Japan, indicating a high and uniform standard of care nationwide. Wide/radical surgical resection and perioperative chemotherapy remain crucial whenever clinically feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.